Vinva Investment Management Ltd Decreases Stake in Hologic, Inc. (NASDAQ:HOLX)

Vinva Investment Management Ltd lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 70.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,409 shares of the medical equipment provider’s stock after selling 77,289 shares during the quarter. Vinva Investment Management Ltd’s holdings in Hologic were worth $2,619,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prentiss Smith & Co. Inc. lifted its holdings in Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after acquiring an additional 130 shares during the period. Covestor Ltd boosted its holdings in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Hologic by 20.3% during the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after buying an additional 140 shares during the last quarter. Finally, Empirical Finance LLC raised its position in Hologic by 1.8% in the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.6 %

Shares of NASDAQ:HOLX opened at $79.44 on Friday. The firm has a fifty day moving average price of $80.28 and a two-hundred day moving average price of $78.42. The company has a market cap of $18.45 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.50 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the company earned $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Royal Bank of Canada increased their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.